私たちの「存在意義・戦略・カルチャー」は、患者さん、株主の皆様、そして社会への貢献に注力し続ける原動力となっています。
","introTitle":"存在意義・戦略・カルチャー","id":2941,"docCheckLogout":null,"pageType":"contentPage","languageCode":"ja-JP","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumbs","links":[{"text":"Home","href":"/ja-jp/","openInNewWindowText":null},{"text":"GSKについて","href":"/ja-jp/company/","openInNewWindowText":null},{"text":"存在意義・戦略・カルチャー","href":"/ja-jp/company/purpose-strategy-and-culture/","openInNewWindowText":null}]},"pageName":"存在意義・戦略・カルチャー","topNav":{"homeLink":{"text":"GSK Homepage","href":"/ja-jp/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":false,"text":"Japan (JP)"},"languageSelector":{"currentLanguage":null,"currentLanguageMobile":null,"selectableLanguages":[]},"darkModeSwitch":{"text":"ダークモード","tooltipText":"ダークモードに切り替えて、より持続可能な世界を一緒に目指しましょう。詳細はこちら
"},"globalSiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"locationSelector":{"text":"Location selector","href":"/ja-jp/locations/","openInNewWindowText":null},"healthCareLink":{"text":"医療関係者向け情報","href":"https://gskpro.com/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"contactUs":{"text":"お問い合わせ","href":"/ja-jp/contact-us/","openInNewWindowText":null},"search":"検索する","backToMain":"Back to main","menu":"Menu","closeMenu":"閉じる","animationsToggleModel":{"enable":true,"activeText":"ビデオを一時停止する","inactiveText":"ビデオを再生する"}},"nodes":[{"tooltip":null,"hasBorderRight":false,"title":"GSKについて","url":"/ja-jp/company/","nodes":[{"title":"存在意義・戦略・カルチャー","url":"/ja-jp/company/purpose-strategy-and-culture/","nodes":[],"isActive":true},{"title":"日本法人 会社概要","url":"/ja-jp/company/at-a-glance/","nodes":[{"title":"今市工場～適切な品質の医薬品を確実にお届けする","url":"/ja-jp/company/at-a-glance/about-imaichi-factory/","nodes":[],"isActive":false}],"isActive":false},{"title":"日本法人社長メッセージ","url":"/ja-jp/company/president-message/","nodes":[],"isActive":false},{"title":"行動指針","url":"/ja-jp/company/policies-codes-and-standards/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"存在意義・戦略・カルチャー","image":{"src":"/media/psrlzurd/gsk_tech_human_image_6k_30056.png?width=329&height=185&format=webp&quality=100&v=1dc0141891810b0","alt":"存在意義・戦略・カルチャー","darkModeSrc":"/media/psrlzurd/gsk_tech_human_image_6k_30056.png?width=329&height=185&format=webp&quality=90&v=1dc0141891810b0"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/company/purpose-strategy-and-culture/","openInNewWindowText":null}},{"text":"採用情報","image":{"src":"/media/nnqgbuwz/_s3a0516_600x337.jpg?width=329&height=185&format=webp&quality=100&v=1dc0141e3b9aa10","alt":"採用情報","darkModeSrc":"/media/nnqgbuwz/_s3a0516_600x337.jpg?width=329&height=185&format=webp&quality=90&v=1dc0141e3b9aa10"},"link":{"text":"SPOTLIGHT ON","href":"/ja-jp/careers/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"イノベーション","url":"/ja-jp/innovation/","nodes":[{"title":"疾患領域","url":"/ja-jp/innovation/therapeutic-areas/","nodes":[{"title":"呼吸器・免疫・炎症","url":"/ja-jp/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"オンコロジー","url":"/ja-jp/innovation/therapeutic-areas/oncology/","nodes":[],"isActive":false},{"title":"HIV","url":"/ja-jp/innovation/therapeutic-areas/hiv/","nodes":[],"isActive":false},{"title":"感染症","url":"/ja-jp/innovation/therapeutic-areas/infectious-diseases/","nodes":[],"isActive":false}],"isActive":false},{"title":"開発パイプライン","url":"/ja-jp/innovation/pipeline/","nodes":[],"isActive":false},{"title":"臨床試験","url":"/ja-jp/innovation/trials-in-people/","nodes":[{"title":"臨床試験とは","url":"/ja-jp/innovation/trials-in-people/about-trials-in-people/","nodes":[],"isActive":false},{"title":"治験結果","url":"/ja-jp/innovation/trials-in-people/simple-trial-data/","nodes":[],"isActive":false},{"title":"治験情報 免責事項","url":"/ja-jp/innovation/trials-in-people/clinical-trial-information-notice/","nodes":[],"isActive":false},{"title":"データ二次利用による臨床研究の公開","url":"/ja-jp/innovation/trials-in-people/clinical-trials-optout/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"開発パイプライン","image":{"src":"/media/xebp324o/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=100&v=1dc01418c117a90","alt":"開発パイプライン","darkModeSrc":"/media/xebp324o/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=90&v=1dc01418c117a90"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/innovation/pipeline/","openInNewWindowText":null}},{"text":"Global Innovation","image":{"src":"/media/pscnepnu/data-and-dna-image.jpg?width=329&height=185&format=webp&quality=100&v=1dce0f7b6a4cd70","alt":"Global Innovation","darkModeSrc":"/media/pscnepnu/data-and-dna-image.jpg?width=329&height=185&format=webp&quality=90&v=1dce0f7b6a4cd70"},"link":{"text":"SPOTLIGHT ON","href":"https://www.gsk.com/en-gb/innovation/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"}}]},{"tooltip":null,"hasBorderRight":false,"title":"製品情報","url":"/ja-jp/products/","nodes":[{"title":"医療用医薬品（患者さま向けくすりの情報）","url":"/ja-jp/products/our-prescription-medicines/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"イノベーション","image":{"src":"/media/qtbfhkic/otsuki-san.jpg?width=329&height=185&format=webp&quality=100&v=1dc01418c60d310","alt":"イノベーション","darkModeSrc":"/media/qtbfhkic/otsuki-san.jpg?width=329&height=185&format=webp&quality=90&v=1dc01418c60d310"},"link":{"text":"SPOTLIGHT ON","href":"/ja-jp/innovation/","openInNewWindowText":null}},{"text":"医療関係の皆さま向けサイト","image":{"src":"/media/s0npmulr/navthumb_stvg_03_2022_port_32_eagle_orange-1_mnav.jpg?width=329&height=185&format=webp&quality=100&v=1dc01418e842840","alt":"医療関係の皆さま向けサイト","darkModeSrc":"/media/s0npmulr/navthumb_stvg_03_2022_port_32_eagle_orange-1_mnav.jpg?width=329&height=185&format=webp&quality=90&v=1dc01418e842840"},"link":{"text":"FEATURED WEBSITE","href":"https://gskpro.com/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"}}]},{"tooltip":null,"hasBorderRight":true,"title":"企業責任","url":"/ja-jp/responsibility/","nodes":[{"title":"アクセス","url":"/ja-jp/responsibility/access/","nodes":[],"isActive":false},{"title":"グローバルへルスとヘルスセキュリティ","url":"/ja-jp/responsibility/global-health-and-health-security/","nodes":[],"isActive":false},{"title":"環境","url":"/ja-jp/responsibility/environment/","nodes":[],"isActive":false},{"title":"インクルージョン ","url":"/ja-jp/responsibility/inclusion/","nodes":[{"title":"日本におけるLGBTQ＋に対する取り組み","url":"/ja-jp/responsibility/inclusion/lgbtqplus/","nodes":[],"isActive":false}],"isActive":false},{"title":"倫理基準","url":"/ja-jp/responsibility/ethical-standards/","nodes":[{"title":"医療機関及び医療関係者との関係の透明性","url":"/ja-jp/responsibility/ethical-standards/transparency-hcps/","nodes":[],"isActive":false},{"title":"患者団体との関係の透明性","url":"/ja-jp/responsibility/ethical-standards/transparency-patient-groups/","nodes":[],"isActive":false},{"title":"贈収賄防止への取り組み","url":"/ja-jp/responsibility/ethical-standards/efforts-to-bribery-prevention/","nodes":[],"isActive":false}],"isActive":false},{"title":"製品ガバナンス","url":"/ja-jp/responsibility/product-governance/","nodes":[],"isActive":false},{"title":"医学・薬学に関連する団体や患者団体への支援","url":"/ja-jp/responsibility/grants-donations/","nodes":[],"isActive":false},{"title":"GSK医学教育事業助成","url":"/ja-jp/responsibility/ime-grant/","nodes":[],"isActive":false},{"title":"患者団体との協働","url":"/ja-jp/responsibility/our-support/","nodes":[],"isActive":false},{"title":"新型インフルエンザへの対応","url":"/ja-jp/responsibility/influenza/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"インクルージョン","image":{"src":"/media/xj0ln5vy/s3a1341_600x350.jpg?width=329&height=185&format=webp&quality=100&v=1dce1c17bf2f510","alt":"インクルージョン","darkModeSrc":"/media/xj0ln5vy/s3a1341_600x350.jpg?width=329&height=185&format=webp&quality=90&v=1dce1c17bf2f510"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/responsibility/inclusion/","openInNewWindowText":null}},{"text":"行動指針","image":{"src":"/media/f5rg2rd1/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dc014185d800e0","alt":"行動指針","darkModeSrc":"/media/f5rg2rd1/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=90&v=1dc014185d800e0"},"link":{"text":"SPOTLIGHT ON","href":"/ja-jp/company/policies-codes-and-standards/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"ニュース","url":"/ja-jp/news/","nodes":[{"title":"報道関係の皆さま向けのお知らせ（プレスリリース）","url":"/ja-jp/news/press-releases/","nodes":[],"isActive":false},{"title":"報道関係の皆さま向けのお問い合わせ","url":"/ja-jp/news/media-contacts/","nodes":[],"isActive":false},{"title":"医療関係の皆さまへのお知らせ","url":"/ja-jp/news/healthcare-professionals/","nodes":[],"isActive":false},{"title":"一般・患者の皆さまのへお知らせ","url":"/ja-jp/news/consumers/","nodes":[],"isActive":false},{"title":"その他のお知らせ","url":"/ja-jp/news/responsibility-news/","nodes":[],"isActive":false},{"title":"注目の取り組み","url":"/ja-jp/news/in-focus/","nodes":[{"title":"疾患情報サイト（患者さま向け）","url":"/ja-jp/news/in-focus/disease-information/","nodes":[],"isActive":false}],"isActive":false},{"title":"私たちのソーシャルメディア","url":"/ja-jp/news/our-social-media/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"疾患情報サイト（患者さま向け）","image":{"src":"/media/xmdfpoex/disease-information_navi.jpg?width=329&height=185&format=webp&quality=100&v=1dc0141d77b8250","alt":"疾患情報サイト（患者さま向け）","darkModeSrc":"/media/xmdfpoex/disease-information_navi.jpg?width=329&height=185&format=webp&quality=90&v=1dc0141d77b8250"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/news/in-focus/disease-information/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"採用情報","url":"/ja-jp/careers/","nodes":[{"title":"Life at GSK – GSKで働く","url":"/ja-jp/careers/life-at-gsk/","nodes":[{"title":"社員の能力開発","url":"/ja-jp/careers/life-at-gsk/developing-our-people/","nodes":[],"isActive":false},{"title":"社員の健康、安全および福利","url":"/ja-jp/careers/life-at-gsk/emploee-health-safety-and-well-being/","nodes":[],"isActive":false},{"title":"パフォーマンスに対する報酬","url":"/ja-jp/careers/life-at-gsk/rewarding-performance/","nodes":[],"isActive":false},{"title":"人事制度のご案内","url":"/ja-jp/careers/life-at-gsk/personnel-system/","nodes":[],"isActive":false}],"isActive":false},{"title":"中途採用","url":"/ja-jp/careers/experienced-professionals/","nodes":[],"isActive":false},{"title":"募集職種・エントリー","url":"/ja-jp/careers/recruitment/","nodes":[],"isActive":false},{"title":"人財本部長からのメッセージ","url":"/ja-jp/careers/message/","nodes":[],"isActive":false},{"title":"社員の声","url":"/ja-jp/careers/our-people-interview/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"社員の声","image":{"src":"/media/cr1piyay/interview_navi.jpg?rxy=0.48166666666666669,0.35207100591715978&width=329&height=185&format=webp&quality=100&v=1dc0141e83a9e50","alt":"社員の声","darkModeSrc":"/media/cr1piyay/interview_navi.jpg?rxy=0.48166666666666669,0.35207100591715978&width=329&height=185&format=webp&quality=90&v=1dc0141e83a9e50"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/careers/our-people-interview/","openInNewWindowText":null}}]}],"skipToContent":null,"skipToSearch":null,"typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=1703","searchFieldPlaceholderText":"検索する","searchPage":"/ja-jp/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"当サイトに掲載されている情報は日本国内に居住されている方のためのもので、日本の事業に関する情報を求める方を対象とした日本のウェブサイトです。
GSKグローバルサイト（英語）はLocation selectorからアクセスいただけます。
© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.
\nGSK plc. Registered in England and Wales No. 3888792.
\nグラクソ・スミスクライン株式会社
東京都港区赤坂1-8-1 赤坂インターシティAIR
これからアクセスしようとしているウェブサイトの内容は、グラクソ・スミスクライン株式会社によって管理されているものではありません。その正確性、安全性、信頼性はグラクソ・スミスクライン株式会社が保証しているものではないことをご了承ください。
","continueText":"続ける","cancelText":"戻る","exclusionUrls":["https://jp.gsk.com","https://jp.gsk.com/","https://gskpro.com/","https://gskpro.com/ja-jp/","https://gskpro.com/ja-jp/yakuzaishi/","https://kusurigsk.jp/","http://kusurigsk.jp/","https://glaxosmithkline.co.jp/","https://glaxosmithkline.co.jp/gsk-chj/","https://glaxosmithkline.co.jp/gsk-chj/products/","https://glaxosmithkline.co.jp/gsk-chj/contact-us/dental-care/","https://glaxosmithkline.co.jp/gsk-chj/contact-us/nonprescription/","https://glaxosmithkline.co.jp/legal/inquire3_1.html","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=medicine1&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=medicine2&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=sideeffect&ref=vaccine","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=research&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=recruit&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=media&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=privacy&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=compliance&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=other&ref=GSKCorporate","https://glaxosmithkline.co.jp/viiv/index.html","https://glaxosmithkline.co.jp/crsf/healthcare/","https://jobs.gsk.com/ja-jp/jobs","https://youtu.be/z5bVnkcBEQo?rel=0","https://www.facebook.com/glaxosmithkline.japan/","https://privacy.gsk.com/ja-jp/privacy-notice/general/","https://btx-a.jp/kao/","https://btx-a.jp/kubi/","https://btx-a.jp/shoni/","http://keishuku.jp/","http://waki-ase.jp/","https://pah.jp/","https://hainyo-onayami.jp/","http://jp.gsk.com/","http://lovesbaby.jp/","https://taijouhoushin-yobou.jp/","http://allwomen.jp/","https://www.broughtbyvaccines.com/ja-jp/","https://jpv5.staging.gsk.com/#market-selector","https://jp.gsk.com/ja-jp/#market-selector","https://kusurigsk.jp/aaa/","https://kusurigsk.jp/aa/","https://kusurigsk.jp/al/","https://kusurigsk.jp/sul/","https://kusurigsk.jp/sere/","https://kusurigsk.jp/sered/","https://kusurigsk.jp/ft/","https://kusurigsk.jp/ftd/","https://kusurigsk.jp/fta/","https://gskpro.com/ja-jp/products-info/relenza/","https://keiren.jp/","https://shakei.jp/","https://shoni.jp/","https://acsprtnavi.c-nuage.jp/~gsk_rg/as/application/toppage","https://acsprtnavi.c-nuage.jp/~gsk/as/application/toppage","https://taijouhoushin-yobou.jp/?utm_source=pr&utm_medium=press_release&utm_campaign=gsk","https://www.broughtbyvaccines.com/ja-jp/?utm_source=pr&utm_medium=press_release&utm_campaign=gsk","https://broughtbyvaccines.com/ja-jp/","https://glaxosmithkline.co.jp/corp/compliance/view/","https://glaxosmithkline.co.jp/corp/compliance/view/index2019.html","https://glaxosmithkline.co.jp/corp/compliance/view/agree_advance.php?t=T-SEARCH","https://glaxosmithkline.co.jp/corp/compliance/patient/agree.html","https://allwomen.jp/","https://www.gskhealthpartner.com/ja-jp/oral-health/","https://glaxosmithkline.co.jp/corp/compliance/view/index2020.html","https://privacy.gsk.com/ja-jp/privacy-notice/","http://www.gsk.com","https://www.gsk.com","https://www.gsk.com/","https://www.gsk.com/en-gb/behind-the-science/","https://supplier.gsk.com/irj/portal/public","https://gsk.i-sight.com/landing-page/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk.com/en-gb/innovation/partnerships/","https://www.gsk.com/media/7473/esg-performance-report-2021.pdf","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/media/8518/policies-and-standards.pdf","https://www.gsk.com/en-gb/company/gsk-at-a-glance/","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/media/8518/policies-and-standards.pdf","https://www.gsk.com/media/9281/gsk-position-on-working-with-third-parties-december-2019.pdf","https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/binding-corporate-rules/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/","https://www.gsk.com/en-gb/innovation/pipeline/","https://www.gsk.com/en-gb/research-and-development/trials-in-people/gsk-study-register-and-patient-level-data/","https://www.gsk.com/en-gb/products/our-product-areas/","https://www.gsk.com/en-gb/responsibility/pricing-and-access/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/","https://www.gsk.com/en-gb/responsibility/product-governance/","https://us.gsk.com/en-us/about-us/us-community-partnerships/stem-education/philadelphia-stem-equity-collective/","https://www.gsk.com/en-gb/responsibility/charitable-partnerships/","https://www.gsk.com/en-gb/company/governance/compliance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/","https://www.gsk.com/en-gb/responsibility/ethical-standards/working-with-third-parties/","https://www.gsk.com/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","https://www.gsk.com/en-gb/responsibility/ethical-standards/human-rights/","https://www.gsk.com/en-gb/responsibility/ethical-standards/use-of-animals/","https://www.gsk.com/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","https://www.gsk.com/en-gb/responsibility/operating-responsibly/ethics-and-values/","https://www.gsk.com/en-gb/careers/","https://www.gsk.com/en-gb/innovation/","https://www.gsk.com/media/9632/q3-2022-results-announcement.pdf","https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-accepts-new-drug-application-for-daprodustat/","https://www.gsk.com/en-gb/media/press-releases/gsk-receives-first-regulatory-approval-for-duvroq-daprodustat-in-japan-for-patients-with-anaemia-due-to-chronic-kidney-disease/","https://www.gsk.com/media/9384/understanding-our-value-chain-carbon-footprint.pdf","https://www.gsk.com/media/9374/understanding-our-value-chain-water-footprint.pdf","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/biodiversity/","https://www.gsk.com/media/9386/q2-2022-results-announcement.pdf","https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Sotrovimab/pdf/SOTROVIMAB-EUA.PDF#nameddest=HCPFS","https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Sotrovimab/pdf/SOTROVIMAB-PATIENT-FACT-SHEET.PDF","https://www.ema.europa.eu/en/news/ema-issues-advice-use-sotrovimab-vir-7831-treating-covid-19","https://www.gsk.com/en-gb/media/press-releases/ema-issues-positive-scientific-opinion-on-gsk-and-vir-biotechnology-s-sotrovimab-for-the-early-treatment-of-covid-19/","https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-us-fda/","https://www.gsk.com/en-gb/about-us/","https://gskpro.com/content/dam/global/hcpportal/ja_JP/products-info/nucala/nucala.pdf","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tre%20legy/pdf/TRELEGY-PI-MG-IFU.PDF","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF","https://www.gsk-clinicalstudyregister.com/study/116855?search=study&search_terms=FF%2FUMEC%2FVI%2B&ps","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trelegy/pdf/TRELEGY-PI-MG-IFU.PDF","https://www.gsksource.com/pharma/content/gsk/source/us/en/brands/nucala/pi/saep.html","https://livlife.com/jp-jp/","https://gskpro.com/ja-jp/products-info/lamictal-epi/adult-dosage/","https://gskpro.com/ja-jp/products-info/lamictal-bp/dosage/","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Breo_Ellipta/pdf/BREO-ELLIPTA-PI-MG.PDF","http://jp.gsk.com","http://jp.gsk.com/","http://www.gsk.com/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/infectious-diseases/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/hiv/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/oncology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/opportunity-driven/","https://viivhealthcare.com/","https://www.youtube.com/embed/zqwxYjuEtaY","https://www.youtube.com/watch?v=ibGWPULYxdM","https://www.facebook.com/GSK","https://twitter.com/GSK","https://www.youtube.com/GSK","http://www.linkedin.com/company/glaxosmithkline","https://www.instagram.com/gsk/","https://www.gsk.com/en-gb/innovation/technologies/","https://www.gsk.com/en-gb/innovation/rd-locations/","https://www.gsk.com/en-gb/media/our-response-to-covid-19/","https://www.gsk.com/speakup","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=donation&ref=GSKCorporate","https://medical.gsk.com/ja-jp/","https://www.egpa.jp/","https://www.gsk.com/en-gb/responsibility/esg-resources/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunologyrespiratory/","https://www.gsk.com/media/10013/q1-2023-results-announcement.pdf","https://viivhealthcare.com/ja-jp/","https://www.gsk.com/media/10423/q2-2023-results-announcement.pdf","https://glaxosmithkline.co.jp/corp/compliance/view/index2021.html","https://www.zensoku.jp/","https://lin.ee/674pSLG","https://www.gsk.com/en-gb/media/press-releases/gsk-and-viiv-healthcare-to-present-scientific-advancements-at-idweek-2023/","https://www.gsk-savethechildren.com/","https://rsvirus.jp/","https://www.gsk.com/media/10667/q3-2023_31-october_final.pdf","https://zensoku.jp/","https://youtu.be/DzEwmhXsaRE","https://www.gsk.com/media/10928/fy-2023-results-announcement.pdf","https://www.gsk.com/media/9281/position-on-working-with-third-parties-2023.pdf","https://with-sle.jp/","https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/","https://www.gsk.com/en-gb/investors/quarterly-results/","https://www.gsk.com/media/11099/q1-2024-results-announcement.pdf","https://www.gsk.com/en-gb/media/press-releases/positive-ruby-phase-iii-data-show-potential-for-jemperli-dostarlimab-combinations-in-more-patients-with-primary-advanced-or-recurrent-endometrial-cancer/","https://www.gsk.com/en-gb/media/press-releases/blenrep-combination-reduced-the-risk-of-disease-progression/","https://www.gsk.com/media/11412/q2-2024-results-announcement.pdf","https://glaxosmithkline.co.jp/corp/compliance/view/index2022.html","https://youtu.be/qNK8ftLE8F8","https://youtu.be/_DJW9Rg5o-M","https://www.gsk.com/en-gb/contact-us/","https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/","https://www.gsk.com/en-gb/responsibility/environment/climate/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/global-health/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/health-security/","https://www.gsk.com/en-gb/responsibility/environment/","https://www.gsk.com/en-gb/responsibility/","https://www.gsk.com/media/11646/q3-2024-results-announcement.pdf","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2023/","https://www.gsk.com/media/11009/esg-performance-report-2023.pdf","https://www.gsk.com/media/10999/environmental-data-2023.pdf","https://www.gsk.com/media/11010/pathway-to-a-net-zero-impact-on-climate.pdf","https://www.gsk.com/media/10534/nature-report-september-2023.pdf","https://www.gsk.com/media/11014/basis-of-reporting-environmental-data-2023.pdf","https://www.gsk.com/en-gb/behind-the-science-magazine/health-equity-gap-medicine-vaccine-access/","https://www.gsk.com/en-gb/innovation/trials/diversity-in-clinical-trials/","https://www.gsk.com/en-gb/responsibility/charitable-investments/","https://www.gsk.com/media/10994/uk-gender-pay-gap-report-2023.pdf","https://www.gsk.com/media/10995/uk-ethnicity-pay-gap-report-2023.pdf","https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-designation-in-china-for-treatment-of-relapsedrefractory-multiple-myeloma/","https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-votes-in-support-of-trials-designed-to-evaluate-jemperli-dostarlimab-gxly-as-a-potential-treatment-for-dmmrmsi-h-locally-advanced-rectal-cancer/","https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/","https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093/","https://www.gsk.com/media/11776/fy-2024-results-announcement.pdf","https://www.gsk.com/en-gb/media/press-releases/depemokimab-delivers-clinically-meaningful-and-statistically-significant-improvements-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp/","https://www.gsk.com/en-gb/investors/","https://kotsuzui-senisho.jp/","https://www.gsk.com/en-gb/innovation/our-leading-scientists/","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=sideeffect&ref=GSKpro","https://www.gsk.com/en-gb/media/press-releases/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsedrefractory-multiple-myeloma/","https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-in-multiple-myeloma-application-accepted-for-review-by-the-european-medicines-agency/","https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-in-relapsedrefractory-multiple-myeloma-accepted-for-regulatory-review-in-japan/","https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combination-accepted-for-priority-review-in-china-in-relapsedrefractory-multiple-myeloma/","https://www.gsk.com/media/11776/fy-2024-results-announcement.pdf","https://www.gsk.com/media/11962/q1-2025-results-announcement.pdf","https://www.gskgrants.com/","https://taijouhoushin-yobou.jp/info-search.html","https://youtu.be/-1PHXPEH298","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2024/","https://www.gsk.com/en-gb/responsibility/responsibility-reports/","https://www.gsk.com/media/11849/environmental-data-2024.pdf","https://www.instagram.com/gsk_japan/","https://supplier.gsk.com/","https://tahatsusei-kotsuzuishu.jp/"]},"settings":{"optionalStylesheetLink":"/media/qm1p21vs/optional_style_u13_jp.css","themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://jp.gsk.com/media/3rjfqjwb/gsk-logo.png?width=104&format=webp&quality=100&v=1dc0141fa7adc10","alt":"GSK Logo","darkModeSrc":"https://jp.gsk.com/media/3rjfqjwb/gsk-logo.png?width=104&format=webp&quality=90&v=1dc0141fa7adc10"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK グラクソ･スミスクライン"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"トップへ戻る","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://jp.gsk.com/ja-jp/company/purpose-strategy-and-culture/"},"tealiumSettings":{"enabled":true,"data":""},"entryPopup":null,"protectedPage":false,"schema":null,"modules":[{"type":"page-nav","ariaLabel":"Secondary","menuItems":[{"title":"私たちの戦略","anchorName":"Ourstrategy"},{"title":"私たちのポートフォリオ","anchorName":"Ourportfolio"},{"title":"私たちの疾患領域","anchorName":"Ourtherapeuticareas"},{"title":"私たちのカルチャー","anchorName":"Ourculture"}],"ariaLabelNextSlide":"Next slide","ariaLabelPreviousSlide":"Previous slide"},{"type":"rich-text","text":"GSKは、サイエンス、テクノロジー、人財を結集し、力を合わせて病に先手を打つことを目的としたグローバルなバイオ医薬品企業です。 私たちは、2030年までに25億の人々の健康に貢献し、株主の皆様と人々への価値創出を目指します。
","useGreyBackground":false,"fullWidth":false},{"type":"spacer","label":""},{"type":"anchor","menuTitle":"私たちの戦略","anchorName":"Ourstrategy","nestedModule":{"type":"rich-text","text":"私たちは、専門性の高いバイオ医薬品企業です。スペシャリティ医薬品、ワクチン、ジェネラル医薬品で、病気を予防し、治療します。
免疫系科学と先進技術に重点を置き、呼吸器・免疫・炎症、オンコロジー、HIV、感染症の4つの主要な治療領域の研究開発に投資を行うことで、人々の健康に大きく貢献します。
私たちはすべてのステークホルダーに対して責任をもって事業を運営します。
研究開発
免疫系科学に対する理解と先端技術を組み合わせることで、人々の生活を一変させる可能性を持つ新薬やワクチンを開発することができます。
パフォーマンス
私たちは力強く成長しており、世界規模で人々の健康に大きな影響をもたらすことができると確信しています。
Our latest performance figures（英語）
\n","useGreyBackground":false,"fullWidth":false}]},{"title":"Responsible business","items":[{"imageOnLeft":true,"image":{"src":"/media/bpppjqy4/img_4374jpg.jpg?format=webp&v=1dcd12650d570c0","alt":"Responsible business","darkModeSrc":"/media/bpppjqy4/img_4374jpg.jpg?format=webp&quality=90&v=1dcd12650d570c0"},"imageCaption":"","text":"責任ある事業活動
責任をもって活動をすることは、ステークホルダーとの信頼関係を築き、維持し、リスクを軽減し、社員の活躍を支え、人々の健康へ大きく貢献することに繋がります。
私たちのスペシャリティ医薬品のポートフォリオは、喘息、がん、HIV、自己免疫疾患である全身性エリテマトーデス(SLE)など、さまざまな疾患の予防と治療に貢献しています。
","image":{"src":"/media/rwxfxcze/hiv-science-image.jpg?width=420&height=336&format=webp&quality=100&v=1dc014189698c10","alt":"HIV","darkModeSrc":"/media/rwxfxcze/hiv-science-image.jpg?width=420&height=336&format=webp&quality=90&v=1dc014189698c10"},"ariaHidden":false,"ariaButtonLabel":"Open スペシャリティ医薬品 modal"},{"type":"flip-card","heading":"ワクチン","text":"私たちのワクチンポートフォリオは、業界においても屈指の幅広さを誇ります。毎年数憶回分のワクチンを供給しており、乳児期から成人・高齢期に至る人生のあらゆる段階における感染症を対象としています。
","image":{"src":"/media/30plrlgp/shingles-science-image-rgb_30991.png?width=420&height=336&format=webp&quality=100&v=1dc014188230250","alt":"Vaccines","darkModeSrc":"/media/30plrlgp/shingles-science-image-rgb_30991.png?width=420&height=336&format=webp&quality=90&v=1dc014188230250"},"ariaHidden":false,"ariaButtonLabel":"Open ワクチン modal"},{"type":"flip-card","heading":"ジェネラル医薬品","text":"ジェネラル医薬品は通常、プライマリ・ケア医が地域医療の現場で処方するものです。
ジェネラル医薬品には、喘息やCOPD治療用の吸入薬、抗生物質まで、さまざまなものがあります。私たちのジェネラル医薬品は、毎日、世界中の何百万人もの人々の生活をより良いものにしています。
私たちは、喘息やCOPD（慢性閉塞性肺疾患）などの疾患を抱えるさまざまな患者グループにおける病気の根本的な要因について深い理解を有しています。
\n私たちの目標は、可能な限り多くの人々を支援するために、幅広いポートフォリオにより、異なる機序を持つ次世代の治療法を用いて呼吸器医療の未来を再定義することです。
\n私たちは、炎症メカニズムに関する数十年の知識を基盤に、間質性肺炎、肝疾患、および腎疾患を対象としています。
","image":{"src":"/media/3o1hkm51/lupus-science-image-rgb_30957.png?width=420&height=336&format=webp&quality=100&v=1dc014188cde850","alt":"Respiratory/ immunology","darkModeSrc":"/media/3o1hkm51/lupus-science-image-rgb_30957.png?width=420&height=336&format=webp&quality=90&v=1dc014188cde850"},"ariaHidden":false,"ariaButtonLabel":"Open 呼吸器・免疫・炎症 modal"},{"type":"flip-card","heading":"オンコロジー","text":"私たちは、がん治療の可能性を変革するため、イノベーションの限界に挑み続けています。病気の経過に変化をもたらし、患者さんの治療アウトカムを再定義し、最終的にはがんの発症を未然に防ぐことを目指しています。血液がんや婦人科がんを中心とした従来の領域から、肺がんや消化器がん、前立腺がん、その他の固形がんにも急速に展開を進めていきます。
","image":{"src":"/media/e22lv5o4/immuno-oncology-science-image-rgb_30979.png?width=420&height=336&format=webp&quality=100&v=1dc014188f371b0","alt":"Oncology","darkModeSrc":"/media/e22lv5o4/immuno-oncology-science-image-rgb_30979.png?width=420&height=336&format=webp&quality=90&v=1dc014188f371b0"},"ariaHidden":false,"ariaButtonLabel":"Open オンコロジー modal"},{"type":"flip-card","heading":"HIV","text":"私たちは約40年にわたり、HIVと共に生きる人々、HIVの予防や注射剤の恩恵を受ける人々の生活の向上に取り組んできました。
\nHIVに関する私たちの取り組みは、ファイザーと塩野義製薬が資本参加し、GSKが過半数を所有するヴィーブヘルスケアが主導しています。ヴィーブヘルスケアは、HIVの治療と予防に専念する唯一の企業であり、HIVの流行を終息させるという高い志を掲げています。
","image":{"src":"/media/rwxfxcze/hiv-science-image.jpg?width=420&height=336&format=webp&quality=100&v=1dc014189698c10","alt":"HIV","darkModeSrc":"/media/rwxfxcze/hiv-science-image.jpg?width=420&height=336&format=webp&quality=90&v=1dc014189698c10"},"ariaHidden":false,"ariaButtonLabel":"Open HIV modal"},{"type":"flip-card","heading":"感染症","text":"私たちの感染症のポートフォリオは業界で最も幅広く多様性に富んだもののひとつであり、これが2030年までに25億の人々の健康に貢献するという目標の実現を支えています。
私たちの優先事項には、季節性感染症、慢性感染症、一般的な小児疾患、そして髄膜炎のような稀ではあるものの重要な疾患が含まれています。また、薬剤耐性により新たな治療法が早急に求められる細菌感染症にも注力しています。
GSKのカルチャーは、社員全員が共有するものです。それは私たちの存在意義をより強固にする原動力、戦略の実現を後押しし、GSKを社員がいきいきと働ける場所にするためのものです。患者さんのための高い志を持ち、結果に責任を持ち、正しいことをするという私たちのカルチャーは、患者さん、株主、社員のために、ともに成果を上げるための基礎となるものです。
\n私たちの行動指針は、GSKと社員が共に前進するためのコミットメントを定めたものです。正しい方法で高い志を実現し、私たちのカルチャーを生かし、GSKをエキサイティングで活気ある職場にします。
","useGreyBackground":false,"fullWidth":false}},{"type":"spacer","label":""},{"type":"varied-module-row","title":"","layoutPattern":1,"modules":[{"type":"image","image":{"src":"https://jp.gsk.com/media/fjilcfd1/gsk_03_2022_port_4_eagle_dark-web-size.jpg?width=1320&format=webp&quality=100&v=1dc01418531aec0","alt":"The Code","darkModeSrc":"https://jp.gsk.com/media/fjilcfd1/gsk_03_2022_port_4_eagle_dark-web-size.jpg?width=1320&format=webp&quality=90&v=1dc01418531aec0"},"link":null,"isFullPageWidth":false,"disableRoundedCorners":false,"expandableToAnOverlay":false,"portraitCrop":true,"cropTo75Width":false,"noCrop":true,"caption":"","title":null,"ariaHidden":false,"ariaFlipCard":"Flip card {title}","ariaImageButton":null},{"type":"list","title":"The Code","titleIcon":null,"list":[{"text":"GSKの行動指針（英語：GSKグローバルサイト）","href":"https://www.gsk.com/en-gb/company/codes-standards-and-reports/#heading1-1","target":"_blank","openInNewWindowText":"新しいウィンドウで開く","type":"href"},{"text":"Codes, standards and reports（英語：GSKグローバルサイト）","href":"https://www.gsk.com/en-gb/company/codes-standards-and-reports/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く","type":"href"}],"bottomLink":null,"text":"","actionButton":null}],"subtext":"","greyBackground":false,"orangeHyperlink":null,"underHyperlink":null},{"type":"varied-signpost-grid","title":"こちらもご覧ください","layoutPattern":4,"pages":[{"title":"採用情報","content":"GSKで働く私たちには、病気に先手を打ちたいという、それぞれの想いがあります。最先端の科学とテクノロジー、そして才能ある人々が力を合わせることで、今後10年の間に25億人の健康に良い影響を与えることを目指しています。ぜひ一緒にこの旅路を歩みませんか？","image":{"src":"/media/0hebnqyu/_s3a0516.jpg?rxy=0.39689578713968959,0.56810631229235875&width=427&height=533&format=webp&quality=100&v=1dc0141e30db2a0","alt":"採用情報","darkModeSrc":"/media/0hebnqyu/_s3a0516.jpg?rxy=0.39689578713968959,0.56810631229235875&width=427&height=533&format=webp&quality=90&v=1dc0141e30db2a0"},"link":{"text":"Careers","href":"/ja-jp/careers/","openInNewWindowText":null}},{"title":"企業責任","content":"GSKでは、サイエンス、テクノロジー、人財を結集し、力を合わせて病に先手を打つ、という存在意義を事業の指針として掲げています。","image":{"src":"/media/242kdja3/_s3a1171.jpg?width=427&height=533&format=webp&quality=100&v=1dc01419272c790","alt":"企業責任","darkModeSrc":"/media/242kdja3/_s3a1171.jpg?width=427&height=533&format=webp&quality=90&v=1dc01419272c790"},"link":{"text":"Responsibility","href":"/ja-jp/responsibility/","openInNewWindowText":null}},{"title":"イノベーション","content":"私たちは、先端技術の力と免疫システムに関する深い知見を組み合わせて、新しい医薬品やワクチンの開発に取り組んでいます。","image":{"src":"/media/qtbfhkic/otsuki-san.jpg?width=427&height=533&format=webp&quality=100&v=1dc01418c60d310","alt":"イノベーション","darkModeSrc":"/media/qtbfhkic/otsuki-san.jpg?width=427&height=533&format=webp&quality=90&v=1dc01418c60d310"},"link":{"text":"Innovation","href":"/ja-jp/innovation/","openInNewWindowText":null}}],"hidePageDescription":false,"useGreyBackground":false},{"type":"rich-text","text":"※本コンテンツは、英国に本社を置くGSKグループを紹介するもので、日本国内に居住している方を対象としています。
","useGreyBackground":false,"fullWidth":true}]}